Skip to content

US · RVTY · MEDICAL - DIAGNOSTICS & RESEARCH

Revvity, Inc. (RVTY) intrinsic value and stock valuation

$145.22as of 2026-11-21 · Mkt cap 12.83B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Revvity, Inc. DCF and intrinsic value

InvestorsCraft values RVTY with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RVTY’s statements →

Revvity, Inc. Graham Number

Graham Number: $55.46d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Waltham, MA 02451 revvity.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.86B-5.5% 5y CAGRd
20112025
Net income
$241.7M-19.8% 5y CAGRd
20112025
Free cash flow
$508.3M-9.3% 5y CAGRd
20112025
Total equity
$7.25B+14.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.86B$2.76B$2.75B$3.31B$3.83B
Operating income$356.6M$410.5M$399.5M$781.1M$1.34B
Net income$241.7M$295.8M-$-118.38M$569.2M$943.2M
EPSd$2.13M$2.41M-$-948.48K$4.5M$8.08M
Operating cash flow$581.8M$628.3M$91.3M$679.8M$1.41B
Capital expenditure-$-73.52M-$-86.65M-$-81.37M-$-85.63M-$-86.02M
Free cash flow$508.3M$541.7M$9.9M$594.2M$1.32B
Total assets$12.2B$12.4B$13.6B$14.1B$15B
Total debt$3.52B$3.33B$4.07B$4.6B$5.16B
Net debt$2.6B$2.16B$3.15B$4.14B$4.56B
Total equity$7.25B$7.67B$7.87B$7.38B$7.14B
Cash and short-term investments$919.9M$1.16B$1.6B$454.4M$603.3M
Income statement
20252024202320222021
Revenue$2.86B$2.76B$2.75B$3.31B$3.83B
Cost of revenue$1.34B$1.43B$1.43B$1.55B$1.55B
Gross profit$1.52B$1.32B$1.32B$1.76B$2.28B
Research and development expenses$215.8M$196.8M$216.6M$221.6M$200.3M
Selling, general and administrative expenses$945.3M$715.3M$706.1M$758M$741.6M
Other expenses-$-1.7M$0.00$0.00$0.00$0.00
Operating expenses$1.16B$912.1M$922.7M$979.6M$942M
Cost and expenses$2.5B$2.34B$2.35B$2.53B$2.49B
Interest income$31.1M$73.2M$72.1M$3.59M$2.24M
Interest expense$92.2M$96.3M$98.8M$104M$102.1M
Depreciation and amortization$302.3M$427.9M$431.8M$427M$311.4M
Ebitda$662.7M$840.3M$713.6M$1.18B$1.62B
Operating income$356.6M$410.5M$399.5M$781.1M$1.34B
Total other income/expenses, net-$-88.36M-$-94.39M-$-216.51M-$-129.28M-$-136.42M
Income before tax$268.3M$316.1M$183M$651.8M$1.2B
Income tax expense$25.8M$33.1M$3.47M$139.2M$314.2M
Net income$241.7M$295.8M-$-118.38M$569.2M$943.2M
Weighted average shares outstanding$113.2M$122.8M$124.7M$126.2M$116.2M
Weighted average diluted shares outstanding$113.2M$122.8M$124.8M$126.4M$116.7M
Balance sheet
20252024202320222021
Cash and short-term investments$919.9M$1.16B$1.6B$454.4M$603.3M
Net receivables$744.7M$632.4M$632.8M$612.8M$707.9M
Inventory$379.5M$367.6M$428.1M$405.5M$425.9M
Total current assets$2.24B$2.35B$3B$3.29B$2.44B
Property, plant and equipment, net$644.7M$649.9M$664.7M$671.3M$649.6M
Goodwill and intangible assets$8.96B$9.1B$9.56B$9.86B$10.4B
Long-term investments$1.16M$124.9M$0.00$144.6M$110.9M
Total non-current assets$9.93B$10B$10.6B$10.8B$12.6B
Total assets$12.2B$12.4B$13.6B$14.1B$15B
Accounts payable$185.5M$167.5M$204.1M$272.8M$324.8M
Short-term debt$588.8M$23.8M$754.8M$502.2M$33.6M
Deferred revenue$0.00$140.2M$135.6M$135.5M$138.1M
Total current liabilities$1.33B$653.1M$1.45B$1.54B$1.21B
Long-term debt$2.93B$3.3B$3.31B$4.09B$5.13B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.59B$4.07B$4.24B$5.2B$6.65B
Capital lease obligations$148.1M$175.1M$165.7M$201.2M$176.7M
Total liabilities$4.92B$4.73B$5.69B$6.75B$7.86B
Common stock$112.3M$120.7M$123.4M$126.3M$126.2M
Retained earnings$6.05B$5.85B$5.61B$4.95B$4.42B
Accumulated other comprehensive income (loss)-$-222.13M-$-396.11M-$-276.69M-$-447.5M-$-162.69M
Total equity$7.25B$7.67B$7.87B$7.38B$7.14B
Total investments$1.16M$124.9M$689.9M$144.6M$110.9M
Total debt$3.52B$3.33B$4.07B$4.6B$5.16B
Net debt$2.6B$2.16B$3.15B$4.14B$4.56B
Cash flow statement
20252024202320222021
Net income$241.2M$283.1M$179.5M$512.7M$889.4M
Depreciation and amortization$405.3M$427.9M$431.8M$427M$311.4M
Stock-based compensation$22.9M$37.8M$41.4M$51.5M$29.7M
Change in working capital-$-96.78M-$-18.3M-$-391.35M-$-262.97M$133M
Accounts receivable-$-101.02M-$-15.97M-$-9M$66.1M$165.6M
Inventory$14.8M$45.1M-$-14.11M-$-48.63M$32.3M
Accounts payable$7.34M-$-26.02M-$-76.43M-$-43.8M-$-7.58M
Net cash provided by operating activities$581.8M$628.3M$91.3M$679.8M$1.41B
Investments in property, plant and equipment-$-73.52M-$-86.65M-$-81.37M-$-85.63M-$-86.02M
Acquisitions, net$0.00$0.00-$-1.93M$6.99M-$-3.98B
Net cash used for investing activities-$-17.35M$776.2M$1.31B-$-132.85M-$-4.11B
Common stock issued$2.92M$0.00$0.00$14.1M$25.1M
Common stock repurchased-$-820.82M-$-369.58M-$-388.88M-$-80.64M-$-73.07M
Dividends paid-$-32.8M-$-34.45M-$-34.97M-$-35.34M-$-32.37M
Net cash used for financing activities-$-855.05M-$-1.13B-$-947.12M-$-661.8M$2.94B
Net change in cash-$-244.59M$250.1M$443.6M-$-148.59M$216.7M
Cash at end of period$919.9M$1.16B$914.4M$470.8M$619.3M
Operating cash flow$581.8M$628.3M$91.3M$679.8M$1.41B
Capital expenditure-$-73.52M-$-86.65M-$-81.37M-$-85.63M-$-86.02M
Free cash flow$508.3M$541.7M$9.9M$594.2M$1.32B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Revvity, Inc.

        Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

        CEO
        Prahlad R. Singh
        Employees
        11K
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Revvity, Inc. (RVTY)?

        Revvity, Inc. (RVTY) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RVTY undervalued?

        RVTY trades at a price of $145.22 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.